Therefore, the development of mutant allele-specific inhibitors for KRASG12D, KRASG12V or KRASG12S, or broad-spectrum pan-KRAS inhibitors, holds significant therapeutic promise for CCA. Here, KRAS is linked to cholangiocarcinoma.